The Filing Desk

Accuray

ARAY · Nasdaq · Health Care · Financials, fiscal 2017 to 2026

ARAY · Last close · November 19, 2026
$2.12
Value Accuray yourself

Accuray's revenue fell 12.3% to $402 million in fiscal 2026. Its operating margin was −6.6%, down from 1.7% a year earlier. Free cash flow was −$13 million. The diluted share count rose 19.3%.

ACCURAY INCORPORATED Latest fiscal year ended June 30, 2026 10-K filed August 27, 2026 · 0001437749-26-029098 Updated
Revenue
$402M
12.3%
Operating margin
−6.6%
8.3 pts
Net income
−$49M
 
Free cash flow
−$13M
 
Return on equity
−80.1%
77.6 pts
Market cap
$295M
Nov 19 close
P/E
—
 

Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on equity is net income as a share of shareholders' equity. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.

About these figures. Return on capital for fiscal 2026 is blank: the 10-K's structured data doesn't include short-term borrowings. Net debt to EBITDA for fiscal 2026 is blank: the 10-K's structured data doesn't include short-term borrowings. Piotroski F-score for fiscal 2026 is blank: the 10-K's structured data doesn't include short-term borrowings.

Charts show fiscal years, from the 10-K filings.

What Accuray does

Accuray makes radiation therapy machines that hospitals and cancer centers use to treat tumors, along with the software to plan treatments and the imaging that guides them. Its two product families are the CyberKnife, a robotic system used for highly focused treatments of tumors anywhere in the body, including the brain and spine, and a line of helical systems (Accuray Stellar, Radixact, Accuray Helix and Tomo C) that deliver radiation in a spiral around the patient.

The company earns money in two ways: selling systems and upgrades, which are large, one-off purchases with long sales and installation cycles, and selling services such as maintenance, support and training to customers who already own its machines. It sells directly in the United States and much of Europe and Asia, and through distributors elsewhere. A joint venture in China that makes and sells its systems there accounted for about 16% of net revenue in the year to June 30, 2026. Accuray says the market for new machines is dominated by Varian, part of Siemens Healthineers, and Elekta.

It builds its systems in Madison, Wisconsin, where it is based, and makes the part that produces the radiation beam in Chengdu, China. It had 809 employees at June 30, 2026, nearly half of them outside the United States.

Its biggest risks, as it describes them

  • Its machines may not win wide enough acceptance from hospitals to support the business, against much larger rivals.
  • High-priced systems with long and uneven sales cycles make revenue and cash flow hard to predict.
  • Its debt, and past breaches of loan conditions that needed waivers from its lenders.
  • Relying on single suppliers for key parts, and on distributors and a joint venture to sell in many countries, including China.
  • Tariffs and trade tensions that have already cut its sales in China and its margins.
From Accuray's annual report on Form 10-K, filed August 27, 2026, in our words; the 10-K has the full description and every risk factor. Updated with each new annual report.

Income statement

Revenue and net income
US$ billions, fiscal years; net losses in red. Revenue on the left axis, net income on the right; zero is the same line on both.
Revenue (left axis)Net income (right axis)
Gross profit, R&D and operating income
US$ billions, fiscal years. Gross profit is revenue minus the cost of what was sold; research and development is one of the costs paid from it; what remains after all operating costs is operating income. Losses in red.
Gross profitResearch and developmentOperating income
Margins
Percent of revenue
GrossOperatingNetFree cash flow

Accuray lost money in fiscal 2026: a net loss of $49 million.

Diluted earnings per share
US$ per share, fiscal years, restated for any stock splits; loss years in red. Where the filings' structured data doesn't give a year's earnings per share, the column is blank.

Returns on capital

Return on capital and on equity
Percent. Return on capital is after-tax operating income over the money invested in the business (debt plus equity, minus cash); return on equity is net income over shareholders' equity. Both use the average of opening and closing balances.
Return on capitalReturn on equity

Balance sheet

Cash and debt
US$ billions, at each fiscal year end. Debt includes finance leases.
Cash and short-term investmentsDebt
Assets, liabilities and equity
US$ billions, at each fiscal year end. Assets equal liabilities plus equity; negative equity in red.
Total assetsTotal liabilitiesShareholders' equity
Debt and liquidity ratios
Times. Debt to equity, current assets over current liabilities, and net debt over EBITDA (a full year's).
Debt to equityCurrent ratioNet debt to EBITDA

Five years at a glance

Fiscal year endFY22FY23FY24FY25FY26
Cash and short-term investments8989695741
Debt incl. finance leases189183180149—
Net debt (negative means net cash)1009411192—
Net debt to EBITDA7.3x13.6x17.4x6.6x—
Debt to equity3.5x3.4x4.0x1.8x—
Interest coverage1.0x0.2x0.0x0.6x−0.8x
Current ratio1.7x1.7x1.7x1.6x1.5x
Quick ratio1.0x1.0x0.9x0.9x0.7x
US$ millions unless stated, at each fiscal year end. Net debt to EBITDA is debt minus cash, divided by operating income before depreciation and amortization: roughly how many years of those earnings the net debt equals. Debt to equity is debt as a multiple of shareholders' equity. Interest coverage is operating income divided by interest expense. The current ratio is current assets over current liabilities; the quick ratio leaves out inventory.

Cash flow

Cash from operations, capital spending and free cash flow
US$ billions, fiscal years. Free cash flow is cash from operations minus capital spending; negative years in red.
Cash from operationsCapital spendingFree cash flow
Stock-based compensation and buybacks
US$ billions, fiscal years. Shares paid to employees (stock-based compensation, a cost that uses no cash) against cash spent buying shares back. Buybacks that only match it leave the share count roughly where it was.
Stock-based compensationShare buybacks
Dividends and buybacks
US$ billions, cash paid in each fiscal year
DividendsShare buybacks
Diluted share count
Weighted-average diluted shares, millions

Projections

Project Accuray's revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.

Insider trades

Over the 12 months between November 20, 2025 and November 19, 2026, 1 insider bought $134,146 of Accuray shares on the open market, and none sold any.

Buys and sells by month
US$ millions, open-market purchases (up) and sales (down) by officers, directors and 10% owners in each month.
BoughtSold
DateInsiderTradeSharesPriceValueFiling
Feb 20, 2026Steven F MayerDirectorBought54,875$0.56$30,730Form 4
Feb 19, 2026Steven F MayerDirectorBought69,000$0.53$36,570Form 4
Feb 18, 2026Steven F MayerDirectorBought126,125$0.53$66,846Form 4
Open-market purchases and sales by officers, directors and 10% owners, from their Form 4 filings with the SEC: one row per person, day and filing, at the day's average price. Grants, option exercises and shares withheld for tax aren't counted. Insiders buy and sell for many reasons, such as taxes, spreading their savings or a plan set up months earlier, so a trade on its own says little about where a company is heading. For information only, not investment advice. Insider trades at all companies

Indicators

Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.

IndicatorFY24FY25FY26
Piotroski F-score2 of 96 of 9—
Rule of 40−3.7%2.4%−15.5%
Altman Z''−1.69−1.53−3.04
Accruals ratio−0.8%−0.9%−9.2%
Piotroski F-score: how many of nine simple tests of profitability, funding and efficiency the company passed in the year (Piotroski, 2000); 8 or 9 is strong, 0 to 2 weak. Rule of 40: revenue growth plus free cash flow margin; software investors treat 40% or more as the bar. Altman Z'': working capital, retained earnings, operating income and equity weighed against assets and liabilities (Altman, 1995); Altman puts above 2.6 in the safe zone and below 1.1 in the distress zone. Accruals ratio: net income minus cash from operations, over average total assets; lower means profit is backed by cash.

The nine F-score tests

TestFY24FY25FY26
Net income is positiveFailFailFail
Cash from operations is positiveFailPassFail
Return on assets roseFailPassFail
Cash from operations exceeds net incomePassPassPass
Debt fell relative to assetsPassPass—
Current ratio roseFailFailFail
Share count didn't riseFailFailFail
Gross margin roseFailPassFail
Revenue rose relative to assetsFailPassFail
F-score2 of 96 of 9—
Companies that report no gross profit are scored on the other eight.

Compare

Put Accuray side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.

Similar companies

CompanyYearRevenue growthOperating marginFree cash flow marginReturn on capitalNet debt to EBITDAF-scoreCompare
AccurayFY26−12.3%−6.6%−3.2%———
MiMedx GroupFY2520.0%15.3%—43.3%−1.9x7Compare
InModeFY25−6.2%23.1%22.8%———Compare
ArtivionFY2513.6%7.7%0.2%3.9%2.7x7Compare
InogenFY253.9%−8.7%−3.9%———Compare
Each company's latest fiscal year. Fiscal years end in different months, so the periods don't line up exactly. Free cash flow margin is free cash flow as a share of revenue. Net debt to EBITDA is explained under the balance sheet, and the F-score under Indicators.

10 years of figures

Fiscal yearFY17FY18FY19FY20FY21FY22FY23FY24FY25FY26
Income statement
Revenue383405419383396430448447458402
Revenue growth−3.9%5.6%3.4%−8.6%3.5%8.5%4.1%−0.2%2.7%−12.3%
Gross profit141162163150160160154143147112
Research and development50575650535857504838
Operating income−10−4112228208−26
Net income−30−24−164−6−5−9−16−2−49
Diluted EPS (US$)−0.36−0.28−0.190.04−0.07−0.06−0.10−0.16−0.02—
Diluted shares (millions)8285889192929598103123
Cash flow
Cash from operations−018−30−238−216−123−7
Capital expenditure56442513446
Free cash flow−512−34−536−73−16−1−13
Dividends paid0000000000
Share buybacks00001400000
Acquisitions0000000000
Stock-based compensation14121189111010106
Balance sheet at fiscal year end
Cash and short-term investments96—771081168989695741
Debt incl. finance leases165131160189178189183180149—
Total assets406379438491480473479469470444
Total liabilities360330388427411420426424389402
Shareholders' equity46495064695354458142
Margins and ratios
Gross margin36.9%39.9%38.8%39.1%40.2%37.2%34.4%32.0%32.0%27.7%
Operating margin−2.6%−0.9%0.1%3.3%5.6%1.9%0.5%0.1%1.7%−6.6%
Net margin−7.7%−5.9%−3.9%1.0%−1.6%−1.2%−2.1%−3.5%−0.3%−12.2%
Free cash flow margin−1.4%3.0%−8.1%−1.3%9.1%−1.7%0.7%−3.5%−0.3%−3.2%
Rule of 40 (growth + FCF margin)−5.3%8.6%−4.7%−9.9%12.6%6.8%4.8%−3.7%2.4%−15.5%
Return on capital−7.1%——6.1%12.8%4.5%1.2%0.3%2.4%—
Return on equity−55.7%−50.2%−33.4%6.7%−9.5%−8.8%−17.4%−31.5%−2.5%−80.1%
Return on assets−6.8%−6.1%−4.0%0.8%−1.3%−1.1%−1.9%−3.3%−0.3%−10.8%
Net debt to EBITDA8.3x—7.5x4.1x2.1x7.3x13.6x17.4x6.6x—
US$ millions unless stated. Where a later 10-K restated a year, the latest filed figure is shown. Download all figures (CSV, US$ millions)
Source: Accuray's Form 10-K filings, from SEC EDGAR. For information only, not investment advice. The Filing Desk is not affiliated with Accuray.